Regorafenib in Pretreated Patients With Progressive CNS Grade 3 or 4 Gliomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas
J. Neurooncol 2022 Jun 18;[EPub Ahead of Print], JM Werner, L Wolf, C Tscherpel, EK Bauer, M Wollring, G Ceccon, M Deckert, A Brunn, R Pappesch, R Goldbrunner, GR Fink, N GalldiksFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.